264.34
price down icon0.29%   -0.78
after-market After Hours: 264.69 0.35 +0.13%
loading
Abbvie Inc stock is traded at $264.34, with a volume of 2.52M. It is down -0.29% in the last 24 hours and down -0.55% over the past month. AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
See More
Previous Close:
$265.12
Open:
$265.49
24h Volume:
2.52M
Relative Volume:
0.44
Market Cap:
$467.12B
Revenue:
$62.82B
Net Income/Loss:
$3.60B
P/E Ratio:
130.38
EPS:
2.0274
Net Cash Flow:
$19.98B
1W Performance:
+0.14%
1M Performance:
-0.55%
6M Performance:
+27.59%
1Y Performance:
+20.96%
1-Day Range:
Value
$262.59
$266.00
1-Week Range:
Value
$261.23
$269.39
52-Week Range:
Value
$190.75
$269.39

Abbvie Inc Stock (ABBV) Company Profile

Name
Name
Abbvie Inc
Name
Phone
(847) 932-7900
Name
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Name
Employee
57,000
Name
Twitter
@abbvie
Name
Next Earnings Date
2026-10-30
Name
Latest SEC Filings
Name
ABBV's Discussions on Twitter

Compare ABBV vs LLY, JNJ, MRK, NVS

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
ABBV icon
ABBV
Abbvie Inc
264.34 468.50B 62.82B 3.60B 19.98B 2.0274
LLY icon
LLY
Lilly Eli Co
1,183.46 1.05T 72.25B 25.28B 10.37B 27.78
JNJ icon
JNJ
Johnson Johnson
271.22 652.31B 97.93B 21.04B 17.80B 8.6278
MRK icon
MRK
Merck Co Inc
148.78 365.09B 65.51B 8.93B 14.12B 3.5532
NVS icon
NVS
Novartis Ag Adr
145.46 272.89B 54.66B 13.58B 16.05B 7.0171

Abbvie Inc Stock (ABBV) Upgrades & Downgrades

Date Action Analyst Rating Change
Aug-13-26 Upgrade Wolfe Research Peer Perform → Outperform
Aug-05-26 Upgrade Erste Group Hold → Buy
Apr-30-26 Upgrade BofA Securities Neutral → Buy
Apr-21-26 Initiated Canaccord Genuity Buy
Feb-25-26 Initiated RBC Capital Mkts Outperform
Feb-20-26 Initiated Barclays Overweight
Jan-08-26 Downgrade Wolfe Research Outperform → Peer Perform
Jan-07-26 Resumed UBS Neutral
Dec-10-25 Upgrade HSBC Securities Hold → Buy
Nov-13-25 Initiated Scotiabank Sector Outperform
Nov-04-25 Downgrade DZ Bank Buy → Hold
Oct-14-25 Downgrade Erste Group Buy → Hold
Oct-01-25 Downgrade HSBC Securities Buy → Hold
Sep-17-25 Upgrade Berenberg Hold → Buy
Aug-12-25 Resumed Piper Sandler Overweight
Aug-07-25 Upgrade Daiwa Securities Neutral → Outperform
May-14-25 Downgrade Citigroup Buy → Neutral
Apr-22-25 Initiated Cantor Fitzgerald Overweight
Dec-10-24 Resumed BofA Securities Neutral
Dec-05-24 Downgrade Daiwa Securities Outperform → Neutral
Nov-22-24 Upgrade Leerink Partners Market Perform → Outperform
Nov-15-24 Initiated Wolfe Research Outperform
Nov-04-24 Upgrade Argus Hold → Buy
Oct-17-24 Initiated Bernstein Mkt Perform
Jun-05-24 Upgrade HSBC Securities Hold → Buy
May-17-24 Initiated Cantor Fitzgerald Overweight
Jan-29-24 Upgrade William Blair Mkt Perform → Outperform
Dec-18-23 Downgrade HSBC Securities Buy → Hold
Dec-11-23 Upgrade Goldman Neutral → Buy
Nov-09-23 Initiated Deutsche Bank Hold
Oct-30-23 Upgrade Barclays Equal Weight → Overweight
Oct-20-23 Resumed UBS Neutral
Sep-29-23 Initiated Raymond James Outperform
Jul-25-23 Initiated William Blair Mkt Perform
Jul-14-23 Initiated HSBC Securities Buy
Apr-05-23 Downgrade Argus Buy → Hold
Mar-01-23 Initiated Guggenheim Buy
Feb-22-23 Downgrade Wolfe Research Outperform → Peer Perform
Feb-10-23 Upgrade SVB Securities Underperform → Market Perform
Nov-18-22 Initiated Credit Suisse Outperform
Nov-08-22 Downgrade Societe Generale Buy → Hold
Aug-01-22 Downgrade Atlantic Equities Overweight → Neutral
May-23-22 Initiated SVB Leerink Underperform
May-06-22 Downgrade Daiwa Securities Outperform → Neutral
Apr-06-22 Resumed Morgan Stanley Overweight
Feb-28-22 Downgrade UBS Buy → Neutral
Feb-03-22 Reiterated BMO Capital Markets Outperform
Feb-03-22 Reiterated Barclays Equal Weight
Feb-03-22 Reiterated BofA Securities Neutral
Feb-03-22 Reiterated Goldman Neutral
Jan-13-22 Initiated Redburn Buy
Jan-12-22 Reiterated BMO Capital Markets Outperform
Dec-09-21 Resumed Wells Fargo Overweight
Nov-23-21 Upgrade Societe Generale Hold → Buy
Jul-27-21 Resumed Truist Buy
Apr-07-21 Resumed RBC Capital Mkts Outperform
Nov-10-20 Resumed Bernstein Outperform
Sep-29-20 Initiated Berenberg Hold
Jun-23-20 Upgrade Atlantic Equities Neutral → Overweight
Jun-09-20 Upgrade Wolfe Research Peer Perform → Outperform
Jun-02-20 Upgrade Argus Hold → Buy
May-18-20 Resumed BofA/Merrill Neutral
May-12-20 Upgrade JP Morgan Neutral → Overweight
May-11-20 Resumed Morgan Stanley Overweight
Apr-20-20 Upgrade RBC Capital Mkts Sector Perform → Outperform
Mar-23-20 Downgrade Societe Generale Buy → Hold
Feb-27-20 Initiated Barclays Equal Weight
Feb-06-20 Initiated Mizuho Buy
Jan-07-20 Initiated RBC Capital Mkts Sector Perform
Dec-26-19 Reiterated Cowen Outperform
Sep-26-19 Upgrade Citigroup Neutral → Buy
Aug-20-19 Upgrade Piper Jaffray Neutral → Overweight
Jun-27-19 Upgrade Wolfe Research Underperform → Peer Perform
Jun-26-19 Upgrade SVB Leerink Mkt Perform → Outperform
May-28-19 Initiated Goldman Neutral
Apr-29-19 Upgrade BMO Capital Markets Underperform → Market Perform
View All

Abbvie Inc Stock (ABBV) Latest News

pulisher
06:31 AM

US FDA approves AbbVie’s drug for Parkinson’s disease - WTAQ

06:31 AM
pulisher
06:21 AM

Investment Outlook Comparison: AbbVie vs. Pfizer - Intellectia AI

06:21 AM
pulisher
06:09 AM

US FDA approves AbbVie's drug for Parkinson's disease - tradingview.com

06:09 AM
pulisher
05:26 AM

AbbVie vs. Pfizer: Which Healthcare Stock Makes Your Portfolio Healthier in 2026? - The Motley Fool

05:26 AM
pulisher
11:01 AM

ABBV vs. JNJ: One of These Dividend Aristocrats Will Crush the Other Over the Next Decade - 247wallst.com

11:01 AM
pulisher
10:30 AM

Allergan Aesthetics - WCIV

10:30 AM
pulisher
10:07 AM

ADARx Pharmaceuticals raises $446 million in upsized IPO - qz.com

10:07 AM
pulisher
08:30 AM

Is AbbVie Inc. (ABBV) Rewriting the Bluechip Stocks Playbook? - Kalkine Media

08:30 AM
pulisher
06:06 AM

AbbVie stock nears its record high after a quarterly beat - AD HOC NEWS

06:06 AM
pulisher
05:08 AM

ADARx Pharmaceuticals Plans $350 Million IPO with AbbVie Investment - Intellectia AI

05:08 AM
pulisher
12:55 PM

AbbVie stock heads into the open after a flat close - AD HOC NEWS

12:55 PM
pulisher
Sep 24, 2026

RBC Capital Sticks to Its Buy Rating for AbbVie (ABBV) - The Globe and Mail

Sep 24, 2026
pulisher
Sep 24, 2026

Reuters Momentum AI Austin Day 1: A New Way to Measure Whether AI Is Actually Paying Off - GlobeNewswire Inc.

Sep 24, 2026
pulisher
Sep 24, 2026

AbbVie vs. Novo Nordisk: Which Drug Giant Stock Is a Better Buy in 2026? - The Globe and Mail

Sep 24, 2026
pulisher
Sep 24, 2026

AbbVie Stays Flat as 6,000-Property AI Hunts Better Molecules - Yahoo Finance

Sep 24, 2026
pulisher
Sep 24, 2026

UChicago Medicine completes construction phase of AbbVie Foundation Cancer Pavilion, bringing new era of cancer care closer to reality - PR Newswire

Sep 24, 2026
pulisher
Sep 24, 2026

AbbVie And Iambic Partner To Accelerate AI-Driven Drug Discovery In Immunology, Neuroscience And Oncology - Pulse 2.0

Sep 24, 2026
pulisher
Sep 24, 2026

AbbVie | 9/24/26 - ktnv.com

Sep 24, 2026
pulisher
Sep 24, 2026

Beyond Imbruvica: Can AbbVie Rebuild Its Oncology Portfolio? - The Globe and Mail

Sep 24, 2026
pulisher
Sep 24, 2026

Pfizer or AbbVie: Which Big Pharma Stock Is the Better Pick? - Zacks Investment Research

Sep 24, 2026
pulisher
Sep 24, 2026

What Is AbbVie (NYSE:ABBV) Adding to Healthcare AI Research? - Kalkine Media

Sep 24, 2026
pulisher
Sep 24, 2026

AbbVie Says Health Canada Issues Notice of Compliance for EPKINLY in Follicular Lymphoma - Yahoo Finance

Sep 24, 2026
pulisher
Sep 24, 2026

AbbVie stock heads into the open after a 0.02 percent gain - AD HOC NEWS

Sep 24, 2026
pulisher
Sep 24, 2026

Prediction: Here's What $10,000 Invested in AbbVie Stock With Dividends Reinvested Could Be Worth in a Decade - Yahoo Finance

Sep 24, 2026
pulisher
Sep 23, 2026

AbbVie: Revenue Pressure And Weakening Earnings Support A 'Sell' (NYSE:ABBV) - Seeking Alpha

Sep 23, 2026
pulisher
Sep 23, 2026

AbbVie stock ends the day 0.2 percent higher at USD 266.45 - AD HOC NEWS

Sep 23, 2026
pulisher
Sep 23, 2026

Nvidia Backed This AI Drug Startup. AbbVie Just Became a Partner Before Its IPO - Yahoo Finance

Sep 23, 2026
pulisher
Sep 23, 2026

What Is AbbVie No Longer Telling You? - Trefis

Sep 23, 2026
pulisher
Sep 23, 2026

2026 2H Healthcare Dividend Roundup: Johnson & Johnson Outshines AbbVie (NYSE:ABBV) - Seeking Alpha

Sep 23, 2026
pulisher
Sep 23, 2026

AbbVie stock hits all-time high of 267.48 USD - Investing.com

Sep 23, 2026
pulisher
Sep 23, 2026

AbbVie (ABBV) Receives a Buy from Scotiabank - The Globe and Mail

Sep 23, 2026
pulisher
Sep 23, 2026

AbbVie stock closes at USD 265.21 as EU approval adds support - AD HOC NEWS

Sep 23, 2026
pulisher
Sep 23, 2026

Why is AbbVie (NYSE:ABBV) in focus amid today’s healthcare stocks discussion? - Kalkine Media

Sep 23, 2026
pulisher
Sep 23, 2026

AbbVie (ABBV) Won EU Approval For RINVOQ In Pediatric Arthritis - Yahoo! Finance Canada

Sep 23, 2026
pulisher
Sep 23, 2026

Where does AbbVie (NYSE:ABBV) go as medicine launches shifts? - Kalkine Media

Sep 23, 2026
pulisher
Sep 23, 2026

AbbVie stock gains 0.3 percent ahead of the open - AD HOC NEWS

Sep 23, 2026
pulisher
Sep 22, 2026

Pediatric Arthritis Treatments: AbbVie Expands RINVOQ to Children With Active pJIA - Trend Hunter

Sep 22, 2026
pulisher
Sep 22, 2026

AbbVie (ABBV) Wins EU Approval for Rinvoq in Children. Why a Small Indication Still Matters - Yahoo Finance

Sep 22, 2026
pulisher
Sep 22, 2026

AbbVie stock ends the day higher at USD 265.51 - AD HOC NEWS

Sep 22, 2026
pulisher
Sep 22, 2026

AbbVie’s Rinvoq Wins 11th EU Approval in Pediatric Arthritis - AskTraders

Sep 22, 2026
pulisher
Sep 22, 2026

AbbVie's Rinvoq Wins EU Approval in Juvenile Idiopathic Arthritis - Yahoo Finance

Sep 22, 2026
pulisher
Sep 22, 2026

New EC approval for AbbVie’s Rinvoq - The Pharma Letter

Sep 22, 2026
pulisher
Sep 22, 2026

Is AbbVie (NYSE:ABBV) Stock Worth Watching Today? - Kalkine Media

Sep 22, 2026
pulisher
Sep 22, 2026

AbbVie receives EU approval for RINVOQ juvenile arthritis treatment - grafa.com

Sep 22, 2026
pulisher
Sep 22, 2026

Allergan Aesthetics Debuts AA Signature™ in the United States with SKIN360, Its First Multimodal Consultation Approach - AbbVie News Center

Sep 22, 2026
pulisher
Sep 22, 2026

AbbVie vs. Pfizer: Which is the Better Dividend Investment? - Intellectia AI

Sep 22, 2026
pulisher
Sep 22, 2026

AbbVie Secures EU Approval for Rinvoq in Juvenile Arthritis - Yahoo Finance

Sep 22, 2026
pulisher
Sep 22, 2026

AbbVie vs. Pfizer: Which Dividend Stock Is the Better Buy in September? - The Globe and Mail

Sep 22, 2026
pulisher
Sep 22, 2026

ADARx sets $350 million IPO terms as AbbVie lines up a stake - The Pharma Letter

Sep 22, 2026
pulisher
Sep 22, 2026

AbbVie’s Rinvoq gains EU approval for juvenile arthritis - Investing.com

Sep 22, 2026
pulisher
Sep 22, 2026

European green light for AbbVie's Rinvoq pediatric expansion - marketscreener.com

Sep 22, 2026

Abbvie Inc Stock (ABBV) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
MRK MRK
$148.78
price up icon 0.54%
JNJ JNJ
$271.22
price up icon 0.20%
NVS NVS
$145.46
price up icon 1.32%
AZN AZN
$166.58
price up icon 1.23%
$414.61
price up icon 2.11%
Cap:     |  Volume (24h):